Whitepaper

Making the Switch to In-House Mycoplasma Testing

Many regulatory guidelines state that cell banks and cultures used in the production of biologics must be tested for mycoplasma. Mycoplasma infections can cause severe problems in manufacturing as these organisms can alter DNA, RNA and modify host cell plasma membrane antigens. As such, mycoplasma can affect the very product being synthesized and lead to a major deviation for a company – halting the recombinant production for months and requiring extensive decontamination processes.

If you are thinking of making the switch, download this whitepaper to learn about:

  • Octapharma's evaluation of the PCR method
  • The process of laboratory set-up including instrument qualifications and software requirements
  • Method development, validation and ensuring assay sensitivity which meet regulatory requirements


If you are thinking of making the switch, download this whitepaper to learn about:

  • Octapharma's evaluation of the PCR method
  • The process of laboratory set-up including instrument qualifications and software requirements
  • Method development, validation and ensuring assay sensitivity which meet regulatory requirements

Access This Whitepaper for FREE Now!

I can withdraw my consent and unsubscribe at any time by e-mailing reply@thermofisher.com.

By submitting my data, I give consent to the collection, processing and use of my personal data in accordance with the Thermo Fisher Scientific Privacy Policy (thermofisher.com/privacypolicy).

Information you provide will be shared with the sponsors for this content. Technology Networks or its sponsors may contact you to offer you content or products based on your interest in this topic. You may opt-out at any time.